Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia.

Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res (2009) 1.53

Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol (2010) 1.31

S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res (2009) 1.25

S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem (2008) 1.18

Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Heart Circ Physiol (2009) 1.16

Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol (2009) 1.10

High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol (2010) 1.07

Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett (2008) 1.03

S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol (2011) 1.02

Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem (2011) 1.00

Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J (2011) 0.99

High-molecular-weight polyethylene glycol protects cardiac myocytes from hypoxia- and reoxygenation-induced cell death and preserves ventricular function. Am J Physiol Heart Circ Physiol (2011) 0.95

Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol (2009) 0.93

Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta (2012) 0.93

Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 0.93

Vincristine attenuates doxorubicin cardiotoxicity. Biochem Biophys Res Commun (2008) 0.93

A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection. Basic Res Cardiol (2011) 0.91

Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin (2012) 0.91

Sphingosine protects aging hearts from ischemia/reperfusion injury: Superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning. Oxid Med Cell Longev (2010) 0.91

A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxid Med Cell Longev (2011) 0.90

Sphingosine kinase regulation and cardioprotection. Cardiovasc Res (2008) 0.90

Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. Basic Res Cardiol (2012) 0.89

The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol (2014) 0.88

Hemovascular Progenitors in the Kidney Require Sphingosine-1-Phosphate Receptor 1 for Vascular Development. J Am Soc Nephrol (2015) 0.86

The impact of bioactive lipids on cardiovascular development. Stem Cells Int (2011) 0.85

Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol (2010) 0.84

Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog Biophys Mol Biol (2010) 0.84

β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy. Circulation (2013) 0.83

High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT (2012) 0.82

Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol (2013) 0.82

Lysophospholipids in coronary artery and chronic ischemic heart disease. Curr Opin Lipidol (2015) 0.81

Cardioprotective activity of a novel and potent competitive inhibitor of lactate dehydrogenase. FEBS Lett (2010) 0.79

Involvement of sphingolipids in ethanol neurotoxicity in the developing brain. Brain Sci (2013) 0.78

Implication of sphingosin-1-phosphate in cardiovascular regulation. Front Biosci (Landmark Ed) (2016) 0.77

Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol (2014) 0.76

Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis. Trends Endocrinol Metab (2016) 0.76

Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75

Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA activation and cardioprotection. J Mol Cell Cardiol (2016) 0.75

Sphingosine 1-phosphate elicits RhoA-dependent proliferation and MRTF-A mediated gene induction in CPCs. Cell Signal (2016) 0.75

High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms. Chem Phys Lipids (2016) 0.75

IL-15: a novel prosurvival signaling pathway in cardiomyocytes. J Cardiovasc Pharmacol (2014) 0.75

Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation. Front Pharmacol (2017) 0.75

β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. J Am Coll Cardiol (2017) 0.75

Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis? Front Pharmacol (2017) 0.75

ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol (2006) 8.36

2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2008) 5.99

2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation (2008) 5.82

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol (2005) 4.16

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol (2003) 3.76

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation (2003) 3.16

The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J (2004) 3.12

2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol (2007) 2.95

International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 2.75

Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell (2003) 2.17

Doxorubicin cardiomyopathy. Cardiology (2009) 1.99

Coronary collateral circulation: its relevance. Catheter Cardiovasc Interv (2013) 1.98

A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res (2007) 1.91

2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation (2007) 1.84

ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation (2008) 1.71

Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J (2002) 1.67

Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63

Relationship between accurate auscultation of a clinically useful third heart sound and level of experience. Arch Intern Med (2006) 1.61

Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res (2008) 1.55

The utility of gestures in patients with chest discomfort. Am J Med (2007) 1.54

Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol (2002) 1.45

Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation (2004) 1.44

Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J Immunol (2002) 1.41

Amiodarone rescue therapy for severe decompensated heart failure initially unsuitable for beta-blockers. J Cardiovasc Pharmacol Ther (2003) 1.38

c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol (2004) 1.30

Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res (2005) 1.30

Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation (2002) 1.30

Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J Immunol (2005) 1.29

A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J (2003) 1.29

Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun (2007) 1.23

Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes. J Neurosci Res (2007) 1.22

Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol (2007) 1.21

Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation (2003) 1.19

Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta (2002) 1.17

Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Heart Circ Physiol (2009) 1.16

Moderate alcohol consumption induces sustained cardiac protection by activating PKC-epsilon and Akt. Am J Physiol Heart Circ Physiol (2002) 1.16

Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation (2005) 1.15

Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol (2007) 1.14

Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol (2008) 1.13

Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1. J Biol Chem (2006) 1.13

Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res (2007) 1.13

Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol (2006) 1.12

Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit (2006) 1.11

A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging (2010) 1.11

Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am J Physiol Heart Circ Physiol (2006) 1.10

Left ventricular remodeling after myocardial infarction: characterization of a swine model on beta-blocker therapy. Comp Med (2009) 1.09

Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem (2003) 1.09

High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail (2006) 1.09

Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun (2008) 1.07

Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J (2005) 1.07

Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res (2008) 1.07

Physical Examination Is Still Necessary and Important. JACC Cardiovasc Imaging (2015) 1.07

Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol (2008) 1.07

High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol (2010) 1.07

Effect of anoxia/reperfusion on the reversible active/de-active transition of NADH-ubiquinone oxidoreductase (complex I) in rat heart. Biochim Biophys Acta (2002) 1.07

Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J Immunol (2003) 1.06

Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovasc Res (2004) 1.06

Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol (2003) 1.04

A rapid radioassay for sphingosine kinase. Anal Biochem (2005) 1.02

S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol (2011) 1.02

Nuclear factor-kappaB-dependent reversal of aging-induced alterations in T cell cytokines. FASEB J (2008) 1.01

Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene (2004) 1.01

Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem Biophys Res Commun (2007) 0.99

A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J Biol Chem (2004) 0.98

Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept (2002) 0.97

Redox-dependent change of nucleotide affinity to the active site of the mammalian complex I. Biochemistry (2007) 0.97

Type 1 sphingosine 1-phosphate G protein-coupled receptor (S1P1) mediation of enhanced IL-4 generation by CD4 T cells from S1P1 transgenic mice. J Immunol (2007) 0.96

Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther (2006) 0.96

Aging enhances release of exosomal cytokine mRNAs by Aβ1-42-stimulated macrophages. FASEB J (2013) 0.95

MnSOD in mouse heart: acute responses to ischemic preconditioning and ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2005) 0.95

Protein kinase C epsilon dependence of the recovery from down-regulation of S1P1 G protein-coupled receptors of T lymphocytes. J Biol Chem (2003) 0.95

Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA (2005) 0.95

N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One (2013) 0.94

Acute vincristine pretreatment protects adult mouse cardiac myocytes from oxidative stress. J Mol Cell Cardiol (2007) 0.94

Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol (2009) 0.93

Th17 augmentation in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor double transgenic mice. J Immunol (2007) 0.93

Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 0.93

Vincristine attenuates doxorubicin cardiotoxicity. Biochem Biophys Res Commun (2008) 0.93

A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One (2012) 0.92

Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol (2008) 0.92